Moderate to severe lung infection
Conditions
Interventions
Experimental group:Cefotaxime sodium and tazobactam sodium for injection, intravenous drip. 2.34 g/time, q8h. Course of treatment: 7 days (the course of treatment depends on the course of the disease
Sponsors
Jiangsu Shengze Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Participants must meet all the following criteria to be included in this study: 1) meet the diagnostic criteria in the "Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults in China (2016 Edition)"; 2) CAP severity: CURB-65 score of 2-3; 3) Age: 18-74 years, gender not specified; 4) Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from this study: 1) do not meet the above diagnostic criteria and inclusion criteria; 2) Patients with secondary pancreatitis caused by tumors or autoimmune diseases; 3) Primary diseases or malignant tumors of the heart, liver, lung, kidney, blood and other systems that are serious and can endanger life; 4) Patients with liver disease, ALT or AST greater than 2 times the upper limit of normal or TBIL greater than 2 times upper limit of normal (excluding patients with normal transaminase but abnormal TBIL); Patients with renal insufficiency, serum creatinine and blood urea nitrogen greater than 1.5 times the upper limit of the normal value; 5) There are people who have a clear allergy to the components of known experimental drugs; 6) Those with a history of alcohol or drug abuse. Patients with poor compliance; 7) Those with mental illness or who are uncooperative.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bacteriology efficacy;Blood routine;C-reactive protein ;Clinical recovery rate after 7 days of treatment; | — |
Countries
China
Contacts
Public ContactYu Lu
Jiangsu Shengze Hospital
Outcome results
None listed